Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor respons… Read more
Eikon Therapeutics, Inc. Common Stock (EIKN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.042x
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has a cash flow conversion efficiency ratio of 0.042x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.74 Million) by net assets ($-571.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eikon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2024)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eikon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lanka Ashok Leyland PLC
CM:ASHON0000
|
N/A |
|
TRAVEL FOOD SERVICES LIMITED
NSE:TRAVELFOOD
|
N/A |
|
GS Retail Co. Ltd.
KQ:007070
|
N/A |
|
WESTMINSTER HLDGS LS-001
F:3W5
|
N/A |
|
TI Fluid Systems PLC
LSE:TIFS
|
0.262x |
|
Nuveen Multi-Asset Income Fund
NYSE:NMAI
|
-0.038x |
|
Konan Technology Inc.
KQ:402030
|
N/A |
|
Together Startup Network Ltd
TA:TGTR
|
-0.149x |
Annual Cash Flow Conversion Efficiency for Eikon Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual cash flow conversion efficiency of Eikon Therapeutics, Inc. Common Stock from 2023 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-571.93 Million | $-134.80 Million | 0.236x | -57.84% |
| 2023-12-31 | $-341.37 Million | $-190.85 Million | 0.559x | -- |